Tag: approval

eVTOLs are on the verge of full commercial manufacturing and approval BOULDER, Colo., July 23, 2025 /PRNewswire/ -- A new report from Guidehouse Research explores electric vertical takeoff...

NMPA grants Syntellix product approval for the world's most important future market with more than 1.4 billion people Syntellix' product approval for China...

NMPA grants Syntellix product approval for the world's most important future market with more than 1.4 billion people Syntellix' product approval for China...

ZUG, Switzerland, July 22, 2025 (GLOBE NEWSWIRE) -- Pharvaris N.V. (“Pharvaris,” Nasdaq: PHVS), a late-stage biopharmaceutical company developing novel, oral bradykinin B2 receptor antagonists to address unmet needs of those living with bradykinin-mediated diseases such as hereditary angioedema (HAE) and acquired angioedema due to C1 inhibitor deficiency (AAE-C1INH), announced today the pricing of an underwritten offering of (i) 8,250,000 of its ordinary shares at a price of $20.00 per share and (ii) to one investor, pre-funded warrants to purchase 500,000 ordinary shares at a price of $19.99 per pre-funded warrant, which represents the per share public offering price for the ordinary shares less the $0.01 per share exercise price for each such pre-funded warrant. All shares and pre-funded warrants in the offering are to be sold by Pharvaris. In addition, Pharvaris has granted the underwriters a 30-day option to purchase up to an additional 1,312,500 ordinary shares at the public offering price, less underwriting discounts and commissions. The gross proceeds to Pharvaris from the offering, before deducting underwriting discounts and commissions and offering expenses, are expected to be approximately $175 million, excluding any exercise of the underwriters’ option to purchase additional shares. The offering is expected to close on or about July 24, 2025, subject to satisfaction of customary closing conditions.

82km of drilling and $9M invested in resource development and exploration in Q4, FY25 PERTH, Western Australia, July 23, 2025 /CNW/ - Westgold Resources Limited...

WOBURN, Mass., July 22, 2025 /PRNewswire/ -- Micro Medical Solutions (MMS), a leading innovator in minimally invasive vascular solutions for Critical Limb Ischemia (CLI),...

CALGARY, AB, July 22, 2025 /CNW/ - Western Energy Services Corp. ("Western" or the "Company") (TSX: WRG) announces the release of its second quarter...

The ROR inhibitors market is witnessing steady growth driven by the increasing understanding of receptor tyrosine kinase-like orphan receptor (ROR) pathways in cancer and...

The ROR inhibitors market is witnessing steady growth driven by the increasing understanding of receptor tyrosine kinase-like orphan receptor (ROR) pathways in cancer and...